Phenotypeca
Phenotypeca is a UK-based synthetic biology company that develops patented yeast strain optimisation technology (QTL) for recombinant protein manufacturing, licensing biosimilar strains (semaglutide, albumin, sargramostim) and offering custom strain services to pharmaceutical, biotech, government, and consumer health clients.
- Company typePrivate
- Founded2018
- HeadquartersNottingham, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Phenotypeca does
Phenotypeca is a UK-based synthetic biology company founded in 2018 and headquartered at BioCity Nottingham that specialises in yeast strain optimisation for recombinant protein manufacturing. The company's proprietary platform uses Quantitative Trait Loci (QTL) technology, an evolutionary breeding method combined with whole-genome functional genomics, to develop high-performance Saccharomyces cerevisiae production strains that deliver 5-20 fold improvements in protein titre compared to traditional genetic engineering or mutagenesis approaches. The platform optimises multiple production traits simultaneously across the entire genome rather than single genes, with all strains animal-free and antibiotic-free by default for regulatory-friendly manufacturing.
The company operates across three product lines. The biosimilars portfolio includes Semaglutide (GLP-1 analogue for obesity/diabetes), Recombinant Albumin (rHSA and rBSA for plasma expansion and cell culture media), and Sargramostim (recombinant GM-CSF for acute radiation syndrome stockpiling). The biological therapeutics pipeline targets VHH antibody therapies for autoimmune conditions (plaque psoriasis, atopic dermatitis), multi-valent HPV vaccine candidates, and a neoantigen cancer vaccine platform. The peptides business supplies recombinant peptides for skincare and consumer health applications where chemical synthesis is uneconomical. Phenotypeca also offers custom strain optimisation services and downstream process support on a project basis.
The company monetises through four revenue streams: territory-specific licensing of patent-protected biosimilar strains with technology transfer support, custom strain development services priced per project, direct API supply to qualified public sector or military buyers, and peptide supply for consumer health brands. Customer segments span pharmaceutical and biotechnology companies, CDMOs, government and military agencies, and beauty/consumer health brands. The company holds granted patents on its QTL optimisation methods and key genetic alleles for each biosimilar, and is supported by the Bill & Melinda Gates Foundation for recombinant albumin development aimed at vaccine accessibility in low and middle-income countries.
Phenotypeca firmographics
Firmographics- Name
- Phenotypeca
- Legal name
- Phenotypeca Ltd.
- Website
- https://phenotypeca.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Phenotypeca is a UK-based synthetic biology company that develops patented yeast strain optimisation technology (QTL) for recombinant protein manufacturing, licensing biosimilar strains (semaglutide, albumin, sargramostim) and offering custom strain services to pharmaceutical, biotech, government, and consumer health clients.
- Ownership category
- akta.pro rank
Phenotypeca industry classification
Industry- Product category
- Biopharmaceutical Manufacturing
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)
- akta.pro secondary industries
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), Recombinant Protein Biosimilars (hormones, enzymes, cytokines) (HLAAAHAB)
Keywords
Where Phenotypeca is headquartered
LocationHeadquarters
- HQ city
- Nottingham
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Phenotypeca business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Biosimilar Licensing: License premium biosimilar strains (Semaglutide, Sargramostim, Recombinant Albumin) to pharmaceutical partners for development and commercialisation. Territory-specific exclusive or non-exclusive licensing with technology transfer support and ongoing API supply options.
- Custom Strain Development Services: Bespoke strain optimisation service with clearly defined stages: initial evaluation (feasibility and titre), breeding cycles and optimisation, stability testing and cell bank creation. Priced on per-project basis.
- Peptide Supply: Bulk recombinant peptide production and supply for skincare, beauty, supplements, and consumer health. Custom development and exclusive access to proprietary peptide pipeline.
- Process Support Services: Technical troubleshooting and support for downstream processing challenges, regulatory submissions, and manufacturing optimisation.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom strain development projects |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Phenotypeca product offering
Product offeringCore offering
Phenotypeca develops and licenses high-performance Saccharomyces cerevisiae production strains for recombinant protein manufacture using its proprietary Quantitative Trait Locus (QTL) strain optimisation platform. The company licenses biosimilars (Semaglutide, Recombinant Albumin, Sargramostim), develops biological therapeutics (VHH antibodies, multi-valent vaccines), supplies recombinant peptides for skincare and consumer health, and provides custom strain optimisation and process support services to pharmaceutical, biotech, CDMO and government clients.
Product overview
Phenotypeca operates as a biotechnology company built around its proprietary QTL (Quantitative Trait Locus) strain optimisation technology platform. The company's portfolio consists of three interconnected product lines: (1) Biosimilars including Semaglutide, Recombinant Albumin, and Sargramostim, which are produced using QTL-optimised yeast strains for superior yield and cost efficiency; (2) Biological Therapeutics encompassing VHH antibody therapies, HPV vaccine candidates, and a neoantigen cancer vaccine platform; and (3) Peptides for skincare and consumer health applications. The QTL platform underpins all offerings, enabling multi-parameter whole-genome optimisation through evolutionary breeding. Services include custom strain optimisation and process support to help partners overcome manufacturing challenges.
Differentiator
Problem solved
Functional benefit
Products and services
- Semaglutide Biosimilar GLP-1 analogue biosimilar for obesity and diabetes care, developed using QTL strain optimisation for high-yield, low-cost semi-recombinant manufacturing; offered to pharmaceutical partners via licensing.
- Recombinant Albumin Animal-free recombinant human serum albumin (rHSA) and recombinant bovine serum albumin (rBSA) produced in Saccharomyces cerevisiae for plasma expansion, cell culture media, and biopharmaceutical formulations; offered to CDMOs and pharma partners via licensing and supply.
- Sargramostim Biosimilar Recombinant GM-CSF biosimilar for acute radiation syndrome (ARS), optimised for national stockpiling against nuclear attack or accident and licensed to government/military customers.
- Recombinant Peptides Recombinant peptides for skincare and consumer health applications, supplied in bulk at commercial scale using QTL-optimised yeast strains for large or complex peptides that are uneconomical to produce via chemical synthesis.
- VHH Antibody Therapy Single-domain antibody (VHH/sdAb) therapeutics targeting plaque psoriasis and atopic dermatitis, developed using QTL-optimised Saccharomyces cerevisiae strains for superior performance; offered via co-development or licensing partnerships.
- HPV Vaccine Candidate Human papillomavirus vaccine candidate developed using multi-valent vaccine platform technology to overcome manufacturing constraints and enable lower-cost or breakthrough-efficacy vaccines.
- Neoantigen Cancer Vaccine Platform Personalised cancer vaccine platform leveraging evolutionary functional genomics for novel therapeutic development.
- Custom Strain Optimisation Services Bespoke strain development services using QTL technology to optimise upstream performance, reduce downstream processing complexity, and achieve cost-efficient bioprocesses; priced per project across feasibility (4-6 weeks), breeding optimisation (10-12 weeks) and stability testing (12-16 weeks) stages.
- Process Support Services Technical troubleshooting support for biologics manufacturing challenges including low titres, scale-up issues, solubility problems, downstream processing, regulatory submissions, and CMC failures.
Companies that use Phenotypeca
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles4 records
Phenotypeca technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Phenotypeca partnerships and signals
Strategic signalScale indicators4 records
Recent moves6 records
Expansion highlights6 records
Phenotypeca competitors and assessment
Company assessmentEmerging players
- Codexis: Codexis is a protein engineering company using directed evolution and computational biology to develop optimised enzymes and strains for pharmaceutical manufacturing. Its CodeEvolver platform is thematically comparable to Phenotypeca's QTL evolution-based strain optimisation, and serves overlapping pharmaceutical/biotech customers.
- Cobra Biologics: Cobra Biologics is a CDMO specialising in recombinant protein and viral vector production using microbial (E. coli and yeast) and mammalian systems. Several Phenotypeca team members previously worked at Cobra, and the company represents a comparable microbial CDMO / contract manufacturing model for the same customer base.
- Bicycle Therapeutics: Bicycle Therapeutics is a UK-based biotechnology company developing peptide-based therapeutics (bicyclic peptides). Comparable to Phenotypeca's peptide supply and novel therapeutic development strategy, with a similar UK origin and peptide/biologic focus.
Broad incumbents
- Amyris: Amyris is a synthetic biology company that engineered yeast strains for industrial-scale production of ingredients (although now largely restructured). Its historical work on yeast-based recombinant production is thematically comparable to Phenotypeca's yeast platform, particularly as a cautionary case study on scaling such platforms.
- GlycoFi (Merck): GlycoFi, acquired by Merck in 2006, was a pioneer in glycoengineered yeast strains for therapeutic protein production. As a successful exit precedent in yeast-based protein expression platform companies, it represents a strategic comparable for Phenotypeca's category and exit trajectory.
- Ginkgo Bioworks: Ginkgo Bioworks is a large, publicly-traded synthetic biology platform company serving pharma, agriculture, and industrial biotech customers with cell engineering services. It represents a broader, well-capitalised platform competitor to Phenotypeca's yeast strain optimisation offering, with much greater scale and scope.
Direct peers
- Albumedix: Albumedix (formerly Novozymes Biopharma / Delta Biotechnology) is a leading supplier of recombinant human albumin (rHSA) produced in Saccharomyces cerevisiae — directly comparable to Phenotypeca's recombinant albumin strain licensing business. Their commercial product Recombumin is the closest commercial competitor in the yeast-based recombinant albumin market.
- Delta Biotechnology: Delta Biotechnology was the original commercial developer of recombinant human serum albumin in yeast. Now operating under Albumedix, it represents the historical reference technology for the recombinant albumin category Phenotypeca is targeting with its QTL-optimised strains.
- Novozymes (Novozymes Biopharma): Novozymes Biopharma (now part of Novonesis) is a long-established yeast-based recombinant protein manufacturer with decades of commercial biopharmaceutical supply. Comparable to Phenotypeca in yeast expression platform technology and recombinant protein production expertise, and a noted previous employer of several Phenotypeca team members.
Regional players
- e-Therapeutics: e-Therapeutics is a UK-based drug discovery company previously led by Phenotypeca CEO Johnny Cordiner. While operating in a different therapeutic modality (network pharmacology and siRNA), it represents a relevant comparable for understanding the CEO's strategic playbook and the UK biotech capital markets environment.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Phenotypeca social profiles
Digital presencePhenotypeca financial estimates
Financial estimateRevenue estimate
Valuation estimate
Phenotypeca leadership team
Management profileNumber of profiles
Profiles17 records
Phenotypeca funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Phenotypeca M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Phenotypeca
What does Phenotypeca do?
Phenotypeca develops and licenses high-performance Saccharomyces cerevisiae production strains for recombinant protein manufacture using its proprietary Quantitative Trait Locus (QTL) strain optimisation platform. The company licenses biosimilars (Semaglutide, Recombinant Albumin, Sargramostim), develops biological therapeutics (VHH antibodies, multi-valent vaccines), supplies recombinant peptides for skincare and consumer health, and provides custom strain optimisation and process support services to pharmaceutical, biotech, CDMO and government clients.
Is Phenotypeca a public or private company?
Phenotypeca is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Phenotypeca founded?
Phenotypeca was founded in 2018. It employs 1 to 10 people.
Where is Phenotypeca based?
Phenotypeca is headquartered in Nottingham, United Kingdom, in the Europe region.
How does Phenotypeca make money?
Four revenue lines are on record. Biosimilar Licensing is the primary driver. The others are custom Strain Development Services, peptide Supply and process Support Services.
Who are Phenotypeca's main competitors?
Emerging players on record are Codexis, Cobra Biologics and Bicycle Therapeutics. Broad incumbents are Amyris, GlycoFi (Merck) and Ginkgo Bioworks. Direct peers are Albumedix, Delta Biotechnology and Novozymes (Novozymes Biopharma). e-Therapeutics is listed as a regional player.
Does Phenotypeca have an API?
No public API is recorded for Phenotypeca.
What industry is Phenotypeca in?
Phenotypeca's product category is Biopharmaceutical Manufacturing. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development), with a secondary code of HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 325414 and its SIC code is 2836.